Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + tremelimumab as first-line treatment for unresectable hepatocellular carcinoma
CTR20222433Phase 3Active
- Sponsor
- MedImmune
- Start
- Feb 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in hepatocellular carcinoma (HCC), sponsored by MedImmune. Started Feb 2023; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20222433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222433.